大麻合法化未降低炎症性肠病患者的阿片类药物处方率:一项双重差分分析
研究利用MarketScan数据开展双重差分分析,比较大麻合法化州与未合法化州炎症性肠病(IBD)患者阿片类药物处方率随时间的变化。共纳入大麻合法化州6240例IBD患者和未合法化州79272例IBD患者。两组阿片类药物处方率随时间均下降且无显著差异(归因差异=0.34,置信区间-13.02至13.70,P=0.96)。作者认为大麻合法化与IBD患者阿片类药物处方率降低无关。
要点
- 大麻合法化州6240例与未合法化州79272例IBD患者的阿片类药物处方率均随时间下降。
- 两组处方率变化无显著差异(归因差异=0.34,置信区间-13.02至13.70,P=0.96)。
- 作者认为大麻合法化与IBD患者阿片类药物处方率降低无关。
核心结论
- 大麻合法化与炎症性肠病患者阿片类药物处方率降低无关;2009年至2016年大麻合法化州与未合法化州的IBD患者阿片类药物处方率均下降,与全国多种疾病中观察到的趋势相似。
研究设计与样本
- 利用MarketScan数据开展双重差分分析,比较随时间变化的大麻合法化州与未合法化州阿片类药物处方率。
- 纳入大麻合法化州6240例IBD患者和未合法化州79272例IBD患者。
主要发现
- 大麻合法化州6240例与未合法化州79272例IBD患者的阿片类药物处方率随时间均下降,两组无显著差异(归因差异=0.34,置信区间-13.02至13.70,P=0.96)。
关键数值与推荐
- 大麻合法化州6240例与未合法化州79272例IBD患者阿片类药物处方率变化的归因差异=0.34,置信区间-13.02至13.70,P=0.96。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Cannabis may provide inflammatory bowel disease (IBD) patients with an alternative to opioids for pain. METHODS: We conducted a difference-in-difference analysis using MarketScan. Changes over time in rates of opioid prescribing were compared in states with legalized cannabis to those without. RESULTS: We identified 6,240 patients with IBD in states with legalized cannabis and 79,272 patients with IBD in states without legalized cannabis. The rate of opioid prescribing decreased over time in both groups and were not significantly different (attributed differential = 0.34, confidence interval -13.02 to 13.70, P = 0.96). DISCUSSION: Opioid prescribing decreased from 2009 to 2016 among patients with IBD in both states with legalized and state without legalized cannabis, similar to what has been observed nationally across a variety of diseases. Cannabis legalization was not associated with a lower rate of opioid prescribing for patients with IBD.
引用
- Noureldin M, Van T, Cohen-Mekelburg S, et al. Legalization of Cannabis Does Not Reduce Opioid Prescribing in Patients With Inflammatory Bowel Disease: A Difference-in-Difference Analysis. Am J Gastroenterol. 2024. PMID: 38767951. doi:10.14309/ajg.0000000000002834
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。